GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » ROA %

Journey Medical (Journey Medical) ROA % : -12.01% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Journey Medical ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Journey Medical's annualized Net Income for the quarter that ended in Dec. 2023 was $-8.57 Mil. Journey Medical's average Total Assets over the quarter that ended in Dec. 2023 was $71.38 Mil. Therefore, Journey Medical's annualized ROA % for the quarter that ended in Dec. 2023 was -12.01%.

The historical rank and industry rank for Journey Medical's ROA % or its related term are showing as below:

DERM' s ROA % Range Over the Past 10 Years
Min: -58.98   Med: -4.23   Max: 12.32
Current: -4.66

During the past 5 years, Journey Medical's highest ROA % was 12.32%. The lowest was -58.98%. And the median was -4.23%.

DERM's ROA % is ranked worse than
65.34% of 1082 companies
in the Drug Manufacturers industry
Industry Median: 1.535 vs DERM: -4.66

Journey Medical ROA % Historical Data

The historical data trend for Journey Medical's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical ROA % Chart

Journey Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
10.71 12.32 -58.98 -29.27 -4.23

Journey Medical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.91 -40.34 -40.40 99.00 -12.01

Competitive Comparison of Journey Medical's ROA %

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Journey Medical's ROA % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's ROA % distribution charts can be found below:

* The bar in red indicates where Journey Medical's ROA % falls into.



Journey Medical ROA % Calculation

Journey Medical's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=-3.853/( (105.16+76.849)/ 2 )
=-3.853/91.0045
=-4.23 %

Journey Medical's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-8.572/( (65.918+76.849)/ 2 )
=-8.572/71.3835
=-12.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Journey Medical  (NAS:DERM) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-8.572/71.3835
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-8.572 / 61.028)*(61.028 / 71.3835)
=Net Margin %*Asset Turnover
=-14.05 %*0.8549
=-12.01 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Journey Medical ROA % Related Terms

Thank you for viewing the detailed overview of Journey Medical's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Journey Medical (Journey Medical) Business Description

Traded in Other Exchanges
N/A
Address
9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.
Executives
Jeffrey Paley director C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith director C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Claude Maraoui director, officer: President & CEO C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch officer: Interim CFO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135

Journey Medical (Journey Medical) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Journey Medical Corp Shares

By GuruFocus Research GuruFocus Editor 05-19-2023